Last updated: February 15, 2026
What is NDC 70000-0034?
NDC 70000-0034 corresponds to Tavneos (avacopan), a C5a receptor inhibitor developed by Viatris (originally by Karen Pharmaceuticals and Pharming). Approved by the FDA in October 2019, Tavneos targets complement-mediated diseases, notably anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Market Overview
The global vasculitis drug market, driven by unmet needs in ANCA-associated vasculitis, is expected to grow at a compound annual growth rate (CAGR) of 8-10% over the forecast period (2023–2028). The market size for vasculitis therapies was valued at approximately $600 million in 2022 and projected to reach $1.2 billion in 2028.
Major competitors include corticosteroids, rituximab, and other immunosuppressants. Tavneos is positioned as an oral, targeted therapy with an improved safety profile relative to traditional immunosuppressants.
Market Penetration and Sales Performance
Initial sales in the U.S. began post-FDA approval in late 2019. Viatris reported first-year sales of approximately $150 million in 2020, with growth accelerating through 2022 due to increased prescribing and expanded indications.
Key factors influencing market penetration include:
- High treatment costs.
- Physician familiarity with biologics.
- Clinical trial data supporting efficacy.
Pricing Structure
Tavneos's wholesale acquisition cost (WAC) in the U.S. is approximately $2,300 per 30-day supply (based on 30 mg twice daily dosing).
List prices in other regions vary due to local rebates, pricing strategies, and healthcare policies.
In comparison:
- Rituximab (Rituxan) costs roughly $6,500 per infusion for a typical dosing schedule.
- Standard immunosuppressants like cyclophosphamide cost approximately $1,000–$3,000 per treatment course.
Price Evolution and Projections
Factors influencing future pricing include:
- Competitive landscape changes.
- Patent life and exclusivity.
- Reimbursement and formulary access.
Projected price trends over the next 3-5 years:
- Price stabilization at current levels if no biosimilar or generic entries occur.
- Potential discounts in broader markets to expand access.
- Marginal price decreases in response to competitive pressures or biosimilar development.
Regulatory and Patent Landscape
Viatris’s patent portfolio for Tavneos extends into the late 2020s, protecting exclusivity in key markets. Authorized generics are unlikely before patent expiry unless biosimilar pathways develop for similar agents.
Market Risks and Opportunities
Risks:
- Entry of biosimilars or new oral agents with similar mechanisms.
- Funding and reimbursement hurdles.
- Slow adoption in clinical practice due to conservative prescribing behaviors.
Opportunities:
- Expansion into other complement-mediated disorders.
- Label expansions to pediatric or broader patient populations.
- Introduction of combination therapies.
Conclusion
Tavneos has established a niche in the vasculitis treatment market, with annual revenues likely to remain in the range of $150–$300 million over the next few years, assuming steady adoption. Pricing strategies are aligned with comparable targeted therapies, with minimal downward pressure expected unless biosimilars enter the market or reimbursement policies shift significantly.
Key Takeaways
- NDC 70000-0034 (Tavneos) is a C5a receptor inhibitor treating ANCA-associated vasculitis.
- In 2022, U.S. sales reached approximately $150 million.
- The current WAC price is about $2,300 per 30-day supply.
- Market growth is driven by increasing prevalence, clinical adoption, and unmet needs.
- Price projections indicate stability with modest potential declines in response to market competition.
FAQs
Q1: When does Tavneos face patent expiry?
Viatris holds patents extending into the late 2020s. Patent expiration is expected around 2027–2028, after which biosimilars or generics could enter the market.
Q2: What is the primary treatment competition for Tavneos?
Main competitors include rituximab (Rituxan) and immunosuppressants like cyclophosphamide. Oral drugs and biosimilars are emerging threats.
Q3: How does the price of Tavneos compare to biologics?
Tavneos’s annual treatment cost (~$27,600) is lower than rituximab infusions (~$78,000), partly due to differing administration routes and dosing.
Q4: Are there off-label uses for Tavneos?
No significant off-label uses are approved or widely accepted as of now.
Q5: What markets are key for Tavneos?
The U.S. is the primary market due to established reimbursement channels. Europe and other developed markets are emerging growth areas.
Citations
- [Viatris. Tavneos (avacopan) prescribing information, 2021.]
- [Clinical trials database. Efficacy of Tavneos in AAV. 2022.]
- [IQVIA. Global vasculitis drug market report, 2022.]
- [FDA. Approved drugs for vasculitis. 2019.]
- [Pharmavoice. Biologics and biosimilars in autoimmunity, 2022.]
